48 results
424B5
SEEL
Seelos Therapeutics Inc
20 May 24
Prospectus supplement for primary offering
4:16pm
coverage. Delisting may adversely impact the perception of our financial condition, cause reputational harm with investors, our employees and parties … financial condition, cause reputational harm with investors, our employees and parties conducting business with us and limit our access to debt
424B5
SEEL
Seelos Therapeutics Inc
30 Jan 24
Prospectus supplement for primary offering
6:05am
and analyst coverage. Delisting may adversely impact the perception of our financial condition, cause reputational harm with investors, our employees
424B5
p08leit yy2nf6pav
30 Nov 23
Prospectus supplement for primary offering
4:58pm
424B5
o8ka6uqgxw 6hfr
28 Nov 23
Prospectus supplement for primary offering
4:06pm
424B5
dz1chz
25 Sep 23
Prospectus supplement for primary offering
6:02am
424B5
dzpsieeo3ae00g ws
12 May 22
Prospectus supplement for primary offering
8:30am
424B5
rti0sgswv2v
21 May 21
Prospectus supplement for primary offering
12:00am
424B5
6s3rx366i0fu48v9j
19 May 21
Prospectus supplement for primary offering
4:08pm